Prospective, Observational Study of the Clinical Outcomes of FVIII Treatment in Adults and Adolescents with Severe Haemophilia A
Prophylaxis using standard or extended half-life FVIII replacement therapies achieves adequate haemostatic control in only about half of patients, with some experiencing very poor outcomes. Real-world data highlight the urgent need to optimize prophylaxis to enhance haemostatic control, ideally achieving a zero ABR and its associated benefits.
Authors
- Liane Khoo
- Hérvè Chambost (ORCID: https://orcid.org/0000-0002-5319-1969)
- Johannes Oldenburg (ORCID: https://orcid.org/0000-0002-1585-4100)
- Annemieke Willemze (ORCID: https://orcid.org/0000-0001-9348-8479)
- Pratima Chowdary
- Michael Wang (ORCID: https://orcid.org/0009-0000-8249-8436)
Institutions
- University of Bonn (DE)
- Inserm (FR)
- Aix-Marseille Université (FR)
- University Hospital Bonn (DE)
- Royal Prince Alfred Hospital (AU)
- The Royal Free Hospital (GB)
- McMaster Children's Hospital (CA)
- Sanofi (Netherlands) (NL)
- University College London (GB)
- University of Colorado Anschutz Medical Campus (US)
- McMaster University (CA)
Publication Details
- Journal
- TH Open
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1055/a-2621-9749
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00